PDS Biotech Registers 110M Shares for Resale, Including 50M Milestone Warrants
PDSB has more than doubled off its 52-week low of $0.195 on light trading volume (0.4× avg).
Summary
PDS Biotech filed an S-3 to register 110 million shares for resale by September 2026 Private Placement investors, including 50 million pre-funded warrants issuable upon FDA submission of the PDS0301 Phase 3 protocol. Nant Capital's 51.72% stake is now fully quantified and tradable.
Key Events · Financing and Capital Events · PDSB
-
110M Share Resale Registration
S-3 registers 110,001,540 shares for resale: 16,502,870 initial shares, 73,498,156 pre-funded warrant shares, and 20,000,514 common warrant shares from the September 2026 Private Placement.
-
50M Milestone Warrants Included
Up to 50,000,000 pre-funded warrants issuable upon FDA submission of the PDS0301 Phase 3 protocol are registered, priced at $0.21967 per warrant for $10M from Nant and $1M from AB Group.
-
Nant Capital 51.72% Stake Quantified
Nant Capital beneficially owns 98,551,890 shares (51.72%), AB Group Ltd. 11,978,291 shares (10.61%), and NIS Holdings 2,920,355 shares (2.76%), all subject to 19.9%/19.99% ownership blockers.
-
No Proceeds to Company from Resales
PDS Biotech receives no proceeds from selling stockholder resales; only cash warrant exercises at $0.22 (common) and $0.00033 (pre-funded) would generate working capital.
Analysis · PDSB · Life Sciences
This S-3 makes tradable the entire September 2026 Private Placement overhang — 110 million shares, including 50 million pre-funded warrants tied to the FDA submission milestone for PDS0301. Nant Capital's 51.72% beneficial ownership stake is now fully quantified, and the registration rights agreement forces this filing within 30 days of closing. The company receives no proceeds from resales, but cash warrant exercises at $0.22 (common) and $0.00033 (pre-funded) could bring in working capital. Against a backdrop of a going-concern warning, $5.6M cash, and Nasdaq delisting risk, this registration is the mechanism that lets Nant and other investors exit — a significant overhang on a stock already trading near $1.41.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.6% of the 1584 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.9M. The 52-week trading range was $0.20 to $1.79. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.